97.20 0.00 (0.00%)
After hours: 5:02PM EDT
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||95.81 - 97.47|
|52 Week Range||67.04 - 104.78|
|PE Ratio (TTM)||48.92|
|Earnings Date||Apr 25, 2018 - Apr 30, 2018|
|Forward Dividend & Yield||1.40 (1.42%)|
|1y Target Est||86.21|
The San Diego-based company said it had net income of 76 cents per share. Earnings, adjusted for amortization costs and restructuring costs, came to 92 cents per share. The results beat Wall Street expectations. ...
ResMed today announced results for its quarter ended March 31, 2018. Revenue for the quarter was $591.6 million, a 15 percent increase compared to the same period of the prior year.
Integra LifeSciences' (IART) revenue growth was primarily driven by high organic revenues, successful progress with Codman integration and progress with the channel expansion strategy.
Thermo Fisher's (TMO) performance in Q1 benefits from a series of product launches alongside a major progress in precision medicine initiatives.
Let's take a look at the factors that are likely to impact the earnings results of a few MedTech bigwigs within the broader Medical universe.
NEW YORK, April 23, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
ResMed's (RMD) sleep apnea patient volume consistently witnesses a steady expansion. We expect this upside to continue in the fiscal third quarter as well.
ResMed , a world-leading connected health company with more than 4 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath.
ResMed today announced it will report its third quarter of fiscal year 2018 results on Thursday, April 26, 2018, after the New York Stock Exchange market closes. A press release with ResMed’s results will be issued after 1:00 p.m.
ResMed (RMD) continues to benefit from solid sales of sleep devices, respiratory care devices, mask systems and software solutions globally.
ResMed (RMD) boosts investor confidence on strength in Software-as-a-Service businesses as well as new mask products and devices.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding RMD totaled $1.87 billion.
ResMed (RMD) consistently invests and expands globally in high-growth markets like China, South Korea, India, Brazil and across the Eastern Europe belt.
ATLANTA , Feb. 28, 2018 /PRNewswire/ -- Brightree, a leading provider of cloud-based software to improve clinical and business performance of post-acute care companies, will show how interoperability and ...
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, Feb. 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ResMed ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Providing more Purchasing Power for Providers at no Additional Cost. HUDSON, Ohio , Feb. 7, 2018 /PRNewswire/ -- GEMCO Medical, a distributor for medical supply providers, is pleased to announce its partnership ...
LabCorp's (LH) Covance Drug Development of late begins to gain traction from Chiltern acquisition, strong organic growth and a favorable foreign currency translation.